The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.

STUDY OBJECTIVE To determine the efficacy of salmeterol alone in a group of patients with moderate asthma with nocturnal worsening of symptoms. DESIGN Double-blind, randomized, placebo-controlled crossover study. SETTING Tertiary care hospital specializing in respiratory diseases. PARTICIPANTS Ten patients with nocturnal asthma. INTERVENTIONS Subjects were randomized to salmeterol, 100 micrograms twice daily, or placebo for 6 weeks with a 1-week washout between treatment periods. Symptoms, nocturnal awakenings, and beta 2-agonist use were recorded daily. Spirometry was performed at weeks 1 and 6 of each period at bedtime and at 4 AM, and methacholine challenge was performed at 4 AM followed by bronchoscopy with BAL. BAL fluid analysis included cell count and differential count, eosinophil cationic protein, Charcot-Leyden crystal protein, leukotriene B4, and thromboxane B2. RESULTS The percentage of nights with awakenings decreased significantly with salmeterol (69.8 +/- 8.7% vs 30.6 +/- 10.8% for placebo and salmeterol, respectively; p = 0.02). The percentage of 24-h days with supplemental inhaled beta 2-agonist use significantly decreased with salmeterol (85.9 +/- 9.4% vs 70.4 +/- 10.1% for placebo and salmeterol, respectively; p = 0.04). There were no significant differences in bronchial reactivity, 4 AM FEV1, overnight percentage change in FEV1, or indexes of airway inflammation. CONCLUSIONS Salmeterol alone improves the number of nocturnal awakenings and supplemental 24-h beta 2-agonist use in nocturnal asthma without significantly altering lung function and airway inflammation.

[1]  S. Wenzel,et al.  Methacholine challenge does not affect bronchoalveolar fluid cell number and many indices of cell function in asthma. , 1995, The European respiratory journal.

[2]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[3]  P. Faurschou,et al.  Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies , 1994, Allergy.

[4]  C. Bolliger,et al.  Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. , 1994, The European respiratory journal.

[5]  K. Jones,et al.  Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. , 1994, Thorax.

[6]  D. Hendrick,et al.  Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. , 1994, American journal of respiratory and critical care medicine.

[7]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[8]  C. Chastang,et al.  Salmeterol compared with slow‐release terbutaline in nocturnal asthma A multicenter, randomized, double‐blind, double‐dummy, sequential clinical trial , 1994, Allergy.

[9]  S. Rennard,et al.  Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. , 1994, JAMA.

[10]  E. Walters,et al.  Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. , 1993, Thorax.

[11]  A. Zwinderman,et al.  Long-Term Effects of a Long-acting ??2-Adrenoceptor Agonist, Salmeterol, on Airways Hyperresponsiveness in Patients with Mild Asthma , 1993 .

[12]  R. Dahl,et al.  The effect of salmeterol on the early‐ and late‐phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X , 1993, Allergy.

[13]  W. Castle,et al.  Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. , 1993, BMJ.

[14]  J. Palmer,et al.  Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group. , 1993, Thorax.

[15]  D. Postma,et al.  Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol. , 1992, The Journal of allergy and clinical immunology.

[16]  P. O'Byrne,et al.  Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. , 1992, The American review of respiratory disease.

[17]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[18]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[19]  M. Johnson,et al.  Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lung , 1991, British journal of pharmacology.

[20]  N. Douglas,et al.  Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. , 1990, BMJ.

[21]  J. Maclouf,et al.  Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. , 1985, Analytical chemistry.

[22]  G. Gleich,et al.  Charcot-Leyden crystal protein and eosinophil granule major basic protein in sputum of patients with respiratory diseases. , 1984, The American review of respiratory disease.

[23]  D. Loegering,et al.  The human eosinophil Charcot-Leyden crystal protein: biochemical characteristics and measurement by radioimmunoassay. , 1980, Journal of immunology.

[24]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.